Thursday, August 2, 2012
Researchers at the University of California, San Francisco and Mount Sinai School of Medicine have
used a Drosophila cancer
model to identify small molecule kinase inhibitors that target a discrete
spectrum of kinases.1 The lead molecule blocked tumor growth in a
mouse model of medullary thyroid carcinoma better than the marketed kinase
vandetanib. An undisclosed
pharma is negotiating to license the IP.
Kotz, J. SciBX 5(30); doi:10.1038/scibx.2012.777
Published online Aug. 2, 2012
1. Dar, A.C. et al. Nature; published online June 6, 2012;
Contact: Kevan M. Shokat, University of California, San
AND INSTITUTIONS MENTIONED
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
Blueprint Medicines, Cambridge, Mass.
Medros Inc., St. Louis, Mo.
Mount Sinai School of Medicine, New York, N.Y.
University of California, San Francisco, Calif.